Galecto, Inc(NASDAQ:GLTO) 
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of sever...
Website: http://www.galecto.com
Founded: 2011
Full Time Employees: 23
CEO: Hans Thalsgård Schambye
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 2.77
H 2.78
L 2.50
C 2.54
V 40,019
10EMA 2.54
20EMA 2.54
60EMA 2.54
120EMA 2.54
250EMA 2.54